Science|Business
Events
Date: 18 October 2012
Venue: UK Representation to the EU, Brussels
 Event Information
  • The Event
  • Supporters
  • Agenda
  • Featured Guests
  • Venue
  • Registration

What is the state of R&D, funding, and infrastructure in Europe? A Science|Business Policy Roundtable

Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.

However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?

Science|Business will host a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.  


Preliminary Agenda

8:30 – 9:00
Registration


9:00 – 9:15
Welcome and Introduction

9:15 –10:00
Session I

EU infrastructure and research support for regenerative therapies as well as human embryonic and other stem cell types



10:00 –10:45
Session II
Open discussion: International best practice and Infrastructure (EU, Japan, US)


10:45 –11:15
Coffee Break

 
11:15 – 12:00
Session III
Comparison of regulation between the EU and EU National Governments


12:00 –13:00
Open discussion: Potential impacts of current regulation on stem cell and regenerative based therapies regarding IP and future commercialization

 
13:00 – 14:00
Buffet Lunch

*
Amelia Andersdotter
Member, European Parliament
*
Arnd Hoeveler
Head of Unit, Advanced Therapies and Systems Medicine, European Commission
*
Emmanuelle Rial-Sebbag
Permanent researcher in biolaw and bioethics, INSERM
*
His Excellency Mr. Jonathan Brenton
UK Ambassador to Belgium
*
Katherine Littler
Policy Adviser, Wellcome Trust
*
Keith Thompson
Chief Executive, Cell Therapy Catapult
*
Magda Chlebus
Director Science Policy, EFPIA
*
Marina Yannakoudakis
Member, European Parliament
*
Rob T.A. Janssen
Secretary-General, Alliance for Advanced Therapies
*
Ruth McKernan
Chief Scientific Officer of Pfizer's Neusentis
*
Suchitra Sumitran-Holgersson
Professor of Transplantation Biology, University of Gothenburg
*
Theo Meert
Senior Director External Innovation in Neurosciences, Janssen Pharmaceutica

UK Representation to the EU

10 Avenue d'Auderghem / Oudergemselaan, 1040 Brussels

The event is now closed for registration. Please contact Science|Business for more information or to be placed on a waiting list in case seats become available network@sciencebusiness.net

*Back   *Top   *Mail to friend
Advertisement